The USD 13.1 support, currently tested, should allow Horizon Pharma to rally again.

From a fundamental viewpoint, the company has a value in line with the industry as its enterprise value ratios show.
Moreover, recently, EPS estimates for the two coming years have been revised upward by analysts. This positive fact opens the way for a better evaluation of the stock by investors.

After several weeks of horizontal fluctuations within the mid-term range USD 14.75 / 22.8, the stock is coming back close to the lower limit of the range.
Moving averages are flat and technical indicators illustrate the oversold situation. The USD 14.75 area could cause a positive reaction for the coming trading sessions, thanks also to a trendline.

Therefore, the proximity of the USD 14.75 support is an opportunity to go long on Horizon Pharma. The first goal is a return in the USD 18.75 resistance area, that is a potential of around 20%. Then, the security has to cross this area in order to re-establish a bullish trend in the mid term. A stop-loss order can be placed under the support currently tested.